Blood Advances · 2017 · 45 citations · 23 references
MedicineHematologyOncologyCancer GeneticsCytogeneticsHematologic OncologyAneuploidyCancer CytogeneticsHematologic MalignanciesHematologic Malignancy TherapyHematopoietic NeoplasmsLymphoid NeoplasmsChromogenic In Situ HybridizationChronic Lymphocytic Leukemia TherapyCytogenetic Prognostic MarkersDna In Situ HybridizationLymphoid Neoplasm CytogeneticsMolecular Prognostic MarkersPrognostic Marker AssessmentPrognostic Marker Evaluation
= .01) were independent risk factors for discontinuing ibrutinib due to transformation. Our results suggest that near-tetraploidy is a potential prognostic marker for Richter transformation to assess in patients going on ibrutinib.
23
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Hematology, Oncology +17
Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +14